Gene, Cell, & RNA Therapy Landscape Report

The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Q1: Approvals of Encelto, Qfitlia, Ruiboshen

In Q1 2025:

  • In the U.S., approvals of Encelto for MacTel type 2 and Qfitlia for hemophilia A or B

  • In China, approval of Ruiboshen, the country's first mesenchymal stem cell therapy, for steroid-refractory acute graft-versus-host disease

  • Continued increase—up to 74% from 58%—in non-genetically modified cell therapy trials initiated for non-oncology indications

 

Report Archives

2024 Archive

Read all available reports from 2024.

2023 Archive

Read all the landscape reports from 2023.

2022 Archive

Read all the landscape reports from 2022.

2021 Archive

Read all the reports from 2021 here.

2025

28th ASGCT Annual Meeting

May 13-17, 2025 | New Orleans

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.